end-stage liver disease
Conditions
Interventions
Remazolam toluene sulfonate group (S group):The experimental drug in the intervention group was Ruimazolam for injection of toluene sulfonic acid(Ruiming, Hengrui, Jiangsu)
Blank control (C group ):The drug used in the control group was normal saline blank controll.
Sponsors
Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged 18-65 years old; 2) Body mass index (BMI) 18 ~ 30 kg/m; 3) ASA classification Level I~III; 4) Proposed orthotopic liver transplantation; 5) Sign the informed consent.
Exclusion criteria
Exclusion criteria: Receptor exclusion criteria: 1) Poor preoperative glycemic control (HbA1c>8.5%); 2) MELD score> 30; 3) Severe cardiopulmonary diseases; 4) Unsteady Preoperative hemodynamics; 5) Preoperative life support (mechanical ventilation, renal replacement therapy, etc.); 6) Severe infection; 7) Anaesthesia drug allergy and patient refusal. Donor liver exclusion criteria: 1) Elderly donors (age>65 years old); 2) History of diabetes of the donors; 3) Preoperative serum sodium level of donors>155 mmol/L; 4) Preoperative AST or ALT level of donors>100 U/L; 5) Length of ICU stay of donors> 7 days; 6) Hemodynamic instability of the donors: systolic blood pressure 10 ug/(kg.min); 7) Steatotic donor liver (bullae steatosis >=30%); 8) Uncontrolled cardiac death donor (uDCD);9) Graft cold ischemia time> 16 h; 10) Graft hot ischemia time> 90 min; 11) Partial graft (reduced volume or split donor liver).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Albumin-bilirubin (Albumin-bilirubin, ALBI) score; | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT;AST;ALB;TBIL;PT;IL-1b;IL-6;IL-8;IL-10;TNF-alpha;CRP;Serum adrenaline;Serum norepinephrine;Serum cortisol;blood glucose;NK cell count;B cell count;CD3 + T cell count;CD4 + T cell count;CD8 +T cell count;The ratio of CD4 +:CD8 +;The ratio of Th 1:Th2;cumulative duration of new hepatic hypotension (MAP<60mmHg);The total dose of norepinephrine used;Liquid inflow and outflow;Use of blood products;Postoperative offline extubation time;Postoperative ICU stay days;Postoperative hospitalization days;The incidence of serious adverse reactions within 30 days after surgery; | — |
Countries
China
Contacts
Public ContactGao Zhifeng
Beijing Tsinghua Changgung Hospital
Outcome results
None listed